Biomea Fusion, Inc. (BMEA) Fair Value 2026

BMEA · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.6 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (43/100)

Quick Summary — As of 2026-08-28, Biomea Fusion, Inc. (BMEA) trades at $1.73. QOC: 4.6/10. Value Trap Risk: 43/100 (WARN). 0/13 models active.

Key Facts

Ticker
BMEA
Price
$1.73
Quality Score
4.6/10
Value Trap Risk
43/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 43 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give BMEA?

0 Intrinsic Value Models vs. Current Price ($1.73)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Biomea Fusion, Inc. (BMEA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Biomea Fusion, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About BMEA?

0 of 13 models are currently active for BMEA. See which stocks rank higher →

How Does BMEA Rank in Biotechnology?

Among 625 Biotechnology stocks, BMEA ranks #416 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Biomea Fusion, Inc. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating BMEA should weigh these sector-specific dynamics alongside our model-derived fair values.

Is BMEA a Value Trap?

CirclFi's Value Trap algorithm assigns BMEA a score of 43/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Biomea Fusion, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Biomea Fusion, Inc.'s fundamental quality profile registers 4.6/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BMEA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Biomea Fusion, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

BDRXBiodexa Pharmaceuticals PlcQOC 4.6NMRANeumora Therapeutics, Inc.QOC 4.6ACXPAcurx Pharmaceuticals, Inc.QOC 4.6AXIMAXIM Biotechnologies, Inc.QOC 4.6OGENOragenics, Inc.QOC 4.6SNTISenti Biosciences Holdings, Inc.QOC 4.6CEROCERo Therapeutics Holdings, Inc.QOC 3.5BBIOBridgeBio Pharma, Inc.QOC 6.4COYACoya Therapeutics, Inc.QOC 5.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: BDRX · NMRA · ACXP · AXIM · OGEN · SNTI · CERO · BBIO · COYA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to BMEA?

5 companies across all industries closest to BMEA’s Quality of Company score of 4.6/10.

VLTInvesco High Income Trust IIQOC 4.6RMSLREMSleep Holdings, Inc.QOC 4.6ASTLAlgoma Steel Group Inc.QOC 4.6FINSAngel Oak Financial Strategies Income Term TrustQOC 4.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: VLT · RMSL · ASTL · FINS · NVDA

Where Does BMEA Sit in CirclFi's Biotechnology Rankings?

BMEA is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Biomea Fusion, Inc.’s Valuation?

What is Biomea Fusion, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Biomea Fusion, Inc. (BMEA). The Quality of Company score is 4.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BMEA overvalued or undervalued right now?

At $1.73, 0 of 0 active models suggest BMEA may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Biomea Fusion, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.6 mean for BMEA?

Biomea Fusion, Inc.'s QOC of 4.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on BMEA?

CirclFi analyzes BMEA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is BMEA a value trap in 2026?

Biomea Fusion, Inc.'s Value Trap score is 43/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Biomea Fusion, Inc. (BMEA) a Quality of Company score of 4.6/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/BMEA/ · Methodology
Primary sources for this BMEA valuation
  • Financial statements: Biomea Fusion, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001840439) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BMEA as of ; valuations recomputed .